magazineImmuPharma collapses on trial failure
Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on 17 April showing how risky early stage drug development really is.
The company’s lead drug Lupuzor failed to show meaningful statistical benefits over a placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez.
ImmuPharma’s share price crashed 85% to 22.7p on the news, leaving the firm’s market value at just £32m. (LMJ)
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell Youinvest.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Big News
- JD Sports is still fighting fit
- ImmuPharma collapses on trial failure
- British Airways owner eyes takeover of Norwegian Air
- Apollo stalks FirstGroup with takeover interest
- Pound pushes to highest level since Brexit vote
- Cyber security firm Avast set for £2.8bn IPO
- Activist investor Elliott rumoured to have Micro Focus in its sights
- Costa spin-off calls at Whitbread gain momentum
